Cyclothiazide

Description: Cyclothiazide (CTZ), a benzothiadiazide (thiazide) diuretic and antihypertensive that was originally introduced in the United States in 1963, is a positive allosteric modulator of ionotropic alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA)-type glutamate receptors with important roles in neurological development and function. It is used frequently to block the desensitization of both native and heterologously expressed AMPA receptors. Specifically, CTZ is known to produce a fast inhibition of AMPA receptor desensitization and a much slower potentiation of the AMPA current. Cyclothiazide is capable of inhibiting rapid desensitization of the ionotropic alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA)-type glutamate receptors, thereby potentiating glutamate responses which may induce seizures activity. Cyclothiazide was also found to inhibit gamma-aminobutyric acid (GABA)-A receptors.

References: Proc Natl Acad Sci U S A. 2006 Feb 21; 103(8): 2943–2947.

Related CAS: 191744-13-5 (CX614); 22503-72-6 (IDRA-21); 742-20-1 (Cyclopenthiazide)

Synonym: CTZ, Cyclothiazide; Anhydron; Renazide; Valmiran; Doburil; Fluidil; Anhydron; Acquirel; Renazide; Tensodiural

Chemical Name: 3-(bicyclo[2.2.1]hept-5-en-2-yl)-6-chloro-3, 4-dihydro-2H-benzo[e][1, 2, 4]thiadiazine-7-sulfonamide 1, 1-dioxide